Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 7:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 605 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Kidney Functional Clear all
Completed No phase listed Observational

Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Calcineurin Inhibitors (CNIs) to Everolimus

NCT03413722
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Tacrolimus, Everolimus
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Oct 25, 2026, 7:24 PM EDT
Recruiting No phase listed Observational

A Multicenter, Prospective Blood Collection Study in a Kidney Transplant Population

NCT07006831
View directory record Official record
Conditions
Kidney Disease, Kidney Transplant, Transplant Recipient, Renal Function, Cell-free DNA, NGS
Interventions
Not listed
Lead sponsor
Devyser Inc.
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
6
States / cities
San Diego, California • San Francisco, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 25, 2026, 7:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Study of Abiraterone Acetate in Male Participants With Impaired Renal Function Compared to Individuals With Normal Renal Function

NCT01715259
View directory record Official record
Conditions
Renal Insufficiency
Interventions
Abiraterone acetate: participants with end-stage renal disease, Abiraterone acetate: matched control participants with normal renal function
Drug
Lead sponsor
Cougar Biotechnology, Inc.
Industry
Eligibility
40 Years to 80 Years · Male only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Nov 19, 2012 · Synced Oct 25, 2026, 7:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Trial Evaluating OPC-34712 in Subjects With Normal Renal Function and Renally Impaired Subjects

NCT01289080
View directory record Official record
Conditions
Schizophrenia, Psychiatric Disorders
Interventions
OPC-34712
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Miami, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 29, 2015 · Synced Oct 25, 2026, 7:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls

NCT07217886
View directory record Official record
Conditions
Renal Impairment
Interventions
S-892216-PO
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
4
States / cities
Orlando, Florida • St. Petersburg, Florida • Tampa, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 25, 2026, 7:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Investigational Study to Evaluate Experimental Medication BMS-986224 in Renally Impaired Participants

NCT03634969
View directory record Official record
Conditions
Cardiac Failure, Myocardial Failure
Interventions
BMS-986224
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Oct 25, 2026, 7:24 PM EDT
Completed No phase listed Observational

Live Kidney Donor Study -Renal Function Study

NCT01158742
View directory record Official record
Conditions
Kidney Donation, Kidney Failure, Kidney Transplantation
Interventions
Glomerular Filtration Rate with Iothalamate, Glomerular Filtration Rate with Iohexol
Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
3
States / cities
Birmingham, Alabama • Minneapolis, Minnesota • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 25, 2026, 7:24 PM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function

NCT00652626
View directory record Official record
Conditions
MDS, AML, Solid Tumors, Multiple Myeloma, Non-Hodgkin's Lymphoma, Hodgkin's Disease
Interventions
azacitidine
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
11
States / cities
Berkeley, California • Hialeah, Florida • Augusta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Oct 25, 2026, 7:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Aleglitazar in Combination With Ibuprofen in Healthy Volunteers

NCT01188317
View directory record Official record
Conditions
Healthy Volunteer
Interventions
aleglitazar, placebo, ibuprofen
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
40 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated May 22, 2012 · Synced Oct 25, 2026, 7:24 PM EDT
Not listed Not applicable Interventional

Flywheel Exercise for CKD

NCT03582982
View directory record Official record
Conditions
Chronic Kidney Disease stage3, Chronic Kidney Disease stage4
Interventions
Eccentric overload exercise
Behavioral
Lead sponsor
Washington D.C. Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 84 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Nov 9, 2018 · Synced Oct 25, 2026, 7:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Renal Function and Renal Impairment.

NCT04831996
View directory record Official record
Conditions
Advanced Malignancies
Interventions
parsaclisib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 82 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
4
States / cities
Tustin, California • Hialeah, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2022 · Synced Oct 25, 2026, 7:24 PM EDT
Completed Phase 2 Interventional Results available

Trial of Oral Glutamine on Mitochondrial Function in CKD

NCT02838979
View directory record Official record
Conditions
Cardiovascular Disease, Sarcopenia, Endothelial Dysfunction, Muscle Mitochondrial Function, Kidney Disease
Interventions
First Intervention (14 days), Washout (3 weeks), Second Intervention (14 days)
Dietary Supplement · Other
Lead sponsor
University of Washington
Other
Eligibility
20 Years to 69 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 14, 2022 · Synced Oct 25, 2026, 7:24 PM EDT
Completed Not applicable Interventional Results available

Impact of Vitamin D Therapies on Chronic Kidney Disease

NCT01222234
View directory record Official record
Conditions
Chronic Kidney Disease (CKD), End-stage Renal Disease (ESRD)
Interventions
Cholecalciferol - CKD, Calcitriol - CKD, Cholecalciferol - non-CKD
Drug · Device
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
21 Years to 90 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Oct 25, 2026, 7:24 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Single Dose Study Investigating the Elimination as Well as the Tolerability of PD 0332334 in Healthy Subjects as Compared to Patients With Impaired Kidney Function.

NCT00721422
View directory record Official record
Conditions
Renal Insufficiency, Pharmacokinetics
Interventions
PD 0332334
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
2
States / cities
Cypress, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 17, 2010 · Synced Oct 25, 2026, 7:24 PM EDT
Terminated Phase 3 Interventional Results available

Everolimus Monotherapy as Immunosuppression After Liver Transplant

NCT04063865
View directory record Official record
Conditions
Kidney Failure
Interventions
Tacrolimus, Everolimus
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 23, 2023 · Synced Oct 25, 2026, 7:24 PM EDT
Completed Not applicable Interventional

Acute Effects of Intradialytic Exercise on Cardiovascular Function in Hemodialysis Patients

NCT02753868
View directory record Official record
Conditions
Kidney Failure
Interventions
exercise, Hemodialysis treatment
Behavioral · Procedure
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Oct 25, 2026, 7:24 PM EDT
Completed Phase 2 Interventional Results available

Study Exploring the Effect of Crizanlizumab on Kidney Function in Patients With Chronic Kidney Disease Caused by Sickle Cell Disease

NCT04053764
View directory record Official record
Conditions
Sickle Cell Disease (SCD)
Interventions
Crizanlizuamb, Standard of Care
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
6
States / cities
Birmingham, Alabama • Chicago, Illinois • Baton Rouge, Louisiana + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 25, 2026, 7:24 PM EDT
Completed Phase 1 Interventional

LY231514 in Treating Patients With Locally Advanced or Metastatic Solid Tumors and Varying Degrees of Kidney Function

NCT00003706
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
pemetrexed disodium
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 28, 2012 · Synced Oct 25, 2026, 7:24 PM EDT
Completed Not applicable Interventional

Impact of an Orthotic Intervention in Children With Peripheral Neuropathy

NCT03655587
View directory record Official record
Conditions
Gait, Drop Foot, Chemotherapy-induced Peripheral Neuropathy, Acute Lymphocytic Leukemia, Pediatric, Rhabdomyosarcoma, Wilms Tumor
Interventions
Solid ankle foot orthotic, Resting night splint
Device
Lead sponsor
Children's Hospitals and Clinics of Minnesota
Other
Eligibility
5 Years to 14 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Minneapolis, Minnesota • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 10, 2023 · Synced Oct 25, 2026, 7:24 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study of the Pharmacokinetics and Safety of Varespladib in Subjects With Normal or Impaired Renal Function

NCT01359579
View directory record Official record
Conditions
Renal Impairment
Interventions
varespladib methyl
Drug
Lead sponsor
Anthera Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
3
States / cities
Orlando, Florida • Minneapolis, Minnesota • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 20, 2012 · Synced Oct 25, 2026, 7:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effect of Renal Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Renal Function

NCT04476849
View directory record Official record
Conditions
Healthy Volunteers, Renal Impairment
Interventions
fezolinetant
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
7
States / cities
Garden Grove, California • Rialto, California • Clearwater, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Oct 25, 2026, 7:24 PM EDT
Completed Phase 1Phase 2 Interventional

Efficacy and Safety of AEB071 Plus Tacrolimus (Converted to Mycophenolic Acid After 3 Months), in Renal Transplant Patients

NCT00403416
View directory record Official record
Conditions
Kidney Transplantation
Interventions
AEB071, Mycophenolic Acid
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
3
States / cities
San Francisco, California • Cleveland, Ohio • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 25, 2026, 7:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics of Entinostat in Adult Subjects With Normal and Impaired Renal Function

NCT03192111
View directory record Official record
Conditions
Renal Impairment, Healthy Volunteer
Interventions
Entinostat
Drug
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 13, 2018 · Synced Oct 25, 2026, 7:24 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar Control

NCT03242018
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Chronic Kidney Disease Stage 4
Interventions
Placebo, Sotagliflozin
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
34
States / cities
Guntersville, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2021 · Synced Oct 25, 2026, 7:24 PM EDT